第99.1展示文本

Breeze Holdings Acquisition Corp. 宣布 与YD Biopharma Limited达成最终协议，将合并

YD生物制药是一家临床阶段生物制药公司，专注于癌症预防诊断，力求改变广泛疾病的治疗方式

交易的专项财务报表显示，合并后的公司预计将拥有近70000万美元的企业价值

拟议的合并预计将在2025年初完成；合并后，预计组合公司将在纳斯达克资本市场上市

YD生物制药最近获得了胰腺癌核甲基化检测的专利、技术和美国授权，并与一家公司达成协议，收购合并结束后将获取乳腺癌检测许可证

2024年9月25日，得克萨斯州欧文– 微风控股收购公司 (OTCQX: BRZH, BRZHR, BRZHW) (“微风” 或 “公司”), 一家公开交易的特殊目的收购公司，已签署最终协议，将与YD生物制药有限公司 (“YD生物制药”), 专注于癌症预防医疗诊断和外泌体治疗药物开发的临床阶段生物制药公司进行合并，有望改变治疗一系列高度未满足医疗需求疾病的潜力。交易完成后，预计合并后的公司将在纳斯达克资本市场上市。

利用科技检测健康问题 及早发现

YD生物医药专注于生物医药企业，为临床试验提供药品和医疗材料。2015年，YD生物医药被诺华任命为临床试验药品供应商，并自此扩展业务范围，包括上市后的发展和供应辅助产品。YD生物医药的使命是通过生物技术的进步创造一个无癌症的世界。

最近，YD生物制药从3D Global Biotech Inc.（“3D Biotech”）获得了专利和技术授权，以开创角膜间充质干细胞及其外泌体用于治疗眼部疾病的应用。YD生物制药推出了新的爱文思控股药品和治疗方案，用于治疗干眼症、青光眼和角膜修复等疾病。YD生物制药旨在通过药店、验光师和其他渠道分销，优化眼科疾病治疗市场。

今年早些时候，YD生物药获得了来自EG生物医学台湾的胰腺癌核甲基化检测的专利、技术和美国市场授权，具有高灵敏度、特异性和准确性。这一合作导致在美国建立了一个专门致力于胰腺癌早期检测和监测技术的独立实验室，标志着YD生物药的研发能力得到了显着扩展，可以与医院、保险公司和药品公司合作，以接触新患者。

YD生物制药公司最近还就乳腺癌检测进行了相关授权谈判，以进一步扩大公司的产品供应。YD生物制药公司正在从EG BioMed台湾处获取在美国、欧盟和亚太地区的爱文思控股乳腺癌检测技术的许可证，该技术具有高灵敏度、特异性和准确性。预计EG BioMed在美国、欧盟和亚太地区的乳腺癌检测技术许可证的收购将与与Breeze的合并交割同时进行。

管理层评论

易达生物医药的创始人、董事长和首席执行官沈以武博士，在药品 行业板块拥有丰富的背景，在一家知名的全球货币药品公司工作过。 受父亲患癌症及随后离世的影响，沈博士致力于根治癌症并帮助人们 通过早期发现避免慢性和痛苦的治疗。

沈博士就拟议中的交易发表了如下声明：“很高兴宣布我们的下一个战略阶段，即通过与Breeze的拟议业务组合在美国上市。自2013年创立以来，我们通过有机创新、许可协议和重要的战略合作取得了重大进展。我们已经制定了加速增长的战略路线图，并有一个引人注目的故事要在美国市场分享，因为我们的目标是实现比以往任何时候都更早地检测健康问题，而且干预程度最小。”

Breeze的董事长兼首席执行官J. Douglas Ramsey博士表示：“从一开始，Breeze的使命就是寻找一家拥有创新和颠覆性技术潜力的公司，以为股东创造巨大增长。我们对与YD生物制药公司的拟议业务合并充满信心，我们认为这是生物技术行业中真正的异常值，具有在各种医疗市场中强劲增长潜力。我们正与他们的团队密切合作，以在2025年初迅速完成交易，并将YD生物制药公司作为一家在美国上市的公司继续前进。”

YD生物制药主要投资亮点

导致实际结果与前瞻性声明中的投影结果实质性不同的关键因素包括以下方面：对于该公司的信贷、流动性和额外融资的风险；股票市场波动性；电子商务行业的增长和趋势变化；该公司的业务活动、重点和计划的变化；包括全球金融状况保持挑战以及新冠肺炎疫情对全球经济影响等一般经济、商业和政治条件的变化；竞争风险；潜在利益冲突；适用法律和法规在本地和外国法规上的变化；广泛的政府监管合规性；与外国市场相关的风险和不确定性；以及其他更全面描述了公司的最新MD&A报告中以及公司2024年4月30日的年度信息表格中风险因素列表所述风险因素。这些风险和不确定性可能会导致实际结果与上述前瞻性陈述在实质上发生根本性的不同。

根据业务组合协议的条款，Breeze和YD生物医药将各自合并为新成立的开曼控股公司的全资子公司，预计命名为“YD生物医药控股有限公司”，并计划在纳斯达克资本市场上市。

假设没有赎回，合并后的公司估计交易后的企业价值为69400万美元，包括约71500万美元的股权价值，2100万美元现金和无债务。现金款项筹集包括Breeze的1010万美元的发帖资金（在赎回和支付任何交易费用之前）和预计的新资本1500万美元。

YD生物医药打算利用此笔款项来扩大生产，并继续开发、审批和推出新技术。

交易已获YD生物制药和Breeze双董事会一致批准。预计将在2025年初完成，需经监管机构和股东批准，以及其他惯例结束条件。更多资讯可在今天由Breeze Holdings向美国证券交易委员会提交的8-k表格中找到。

完成交易后，YD生物制药将由创办人、董事长和首席执行官沈以恬博士领导。吴正芬将担任首席医疗官，而蔡美将担任首席业务官。

Advisors

ArentFox Schiff LLP and Ogier are acting as legal advisors to YD Biopharma. I-Bankers Securities, Inc. is acting as financial advisor to Breeze Holdings. Woolery & Co. PLLC is acting as legal advisor to Breeze Holdings.

About YD Biopharma

YD Biopharma Limited is a clinical-stage biopharmaceutical company focusing on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. Through continuous effort and innovation, the Company has also become a recognized supplier of clinical trial drugs and has begun developing and supplying post-market auxiliary products.

For more information, please visit www.yd-biopharma.com.

About Breeze Holdings Acquisition Corp.

Breeze Holdings is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses or entities.

Additional Information and Where to Find It

This press release relates to a proposed business combination transaction involving Breeze Holdings and YD Biopharma. In connection with the proposed transaction, a newly-formed Cayman exempted company expected to be named “YD Biopharma Holdings Limited” (“YD Holdings”) intends to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4 that will include a proxy statement of Breeze and that also will constitute a prospectus of YD Holdings with respect to the ordinary shares of YD Holdings to be issued in the proposed transaction (the “Proxy Statement/Prospectus”). This document is not a substitute for the Proxy Statement/Prospectus. The definitive Proxy Statement/Prospectus (if and when available) will be delivered to Breeze Holdings’ and YD Biopharma’s stockholders. Breeze Holdings may also file other relevant documents regarding the proposed transaction with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF BREEZE HOLDINGS AND YD BIOPHARMA AND OTHER INTERESTED PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BREEZE HOLDINGS, YD HOLDINGS, YD BIOPHARMA, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and security holders of Breeze Holdings and YD Biopharma may obtain free copies of the Registration Statement and Proxy Statement/Prospectus (if and when available) and other documents that are filed or will be filed with the SEC by Breeze Holdings through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Breeze Holdings will be available free of charge at Breeze Holdings Acquisition Corp., 955 W. John Carpenter Fwy., Suite 100-929, Irving, TX 75039, attention: J. Douglas Ramsey.

Participants in the Solicitation

Breeze Holdings, YD Biopharma and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Breeze Holdings and YD Biopharma in respect of the proposed transaction. Information about Breeze Holdings’ directors and executive officers and their ownership of Breeze Holdings common stock is set forth in Breeze Holdings’ filings with the SEC, including its Annual Report on Form 10-K/A for the year ended December 31, 2023 filed with the SEC on April 25, 2024 (the “Annual Report”). To the extent that holdings of Breeze Holdings’ securities have changed since the amounts included in the Annual Report, such changes have been or will be reflected on Statements of Change in Ownership of Form 4 filed with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described in the preceding paragraph.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements regarding the anticipated benefits and impact of the proposed transaction on the combined company’s business and future financial and operating results, the anticipated timing of closing of the proposed transaction, the anticipated growth of the industries and markets in which YD Biopharma competes, the success and customer acceptance of YD Biopharma’s product and service offerings and other aspects of YD Biopharma’s operations, plans, objectives, opportunities, expectations or operating results, the expected ownership structure of the combined company and the likelihood and ability of the parties to successfully consummate the proposed transaction. Words such as “may,” “should,” “will,” “believe,” “expect,” “anticipate,” “intend,” “estimated,” “target,” “project,” and similar phrases or words of similar meaning that denote future expectations or intent regarding the combined company’s financial results, operations and other matters are intended to identify forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Such forward-looking statements are based upon the current beliefs and expectations of management and are inherently subject to significant business, economic and competitive risks, uncertainties and other factors, both known and unknown, which are difficult to predict and generally beyond our control and that may cause actual results and the timing of future events to differ materially from the results and timing of future events anticipated by the forward-looking statements in this press release, including but not limited to: (i) the ability of the parties to complete the proposed transaction within the time frame anticipated or at all, which may adversely impact the price of Breeze Holdings’ securities; (ii) the failure to realize the anticipated benefits of the proposed transaction or those benefits taking longer than anticipated to be realized; (iii) the risk that the proposed transaction may not be completed by Breeze Holdings’ business combination deadline and the potential failure to obtain further extensions of the business combination deadline if sought by Breeze Holdings; (iv) the failure to satisfy the conditions to the consummation of the proposed transaction, including the adoption of the definitive merger agreement by the stockholders of Breeze Holdings or YD Biopharma, the receipt of any required governmental or regulatory approvals or the failure to meet the Nasdaq listing standards in connection with the closing of the proposed transaction; (v) the lack of a third party valuation in determining whether or not to pursue the proposed transaction; (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive merger agreement; (vii) the impact of the COVID-19 pandemic or related governmental or regulatory orders ; (viii) the effect of the announcement or pendency of the proposed transaction on YD Biopharma’s business relationships, performance and business generally; (ix) risks that the proposed transaction disrupts current plans and operations of YD Biopharma and any potential difficulties in YD Biopharma employee retention as a result of the proposed transaction; (x) the outcome of any legal proceedings that may be instituted against YD Biopharma or Breeze Holdings related to the definitive merger agreement or the proposed transaction or any product liability or regulatory lawsuits or proceedings relating to YD Biopharma’s products or services; (xi) the ability to maintain the listing of YD Holdings’ securities on the Nasdaq Capital Market after the closing of the proposed transaction; (xii) potential volatility in the price of Breeze Holdings’ securities due to a variety of factors, including changes in the competitive and highly regulated industries in which YD Biopharma operates, variations in performance across competitors, changes in laws and regulations affecting YD Biopharma’s business, and changes in the combined company’s capital structure; (xiii) the ability to implement business plans, identify and realize additional opportunities and achieve forecasts and other expectations after the completion of the proposed transaction; (xiv) the risk of downturns and the possibility of rapid change in the highly competitive industries in which YD Biopharma operates or the markets that YD Biopharma targets; (xv) the inability of YD Biopharma and its current and future collaborators to successfully develop and commercialize YD Biopharma’s products and services in the expected time frame or at all; (xvi) the risk that the combined company may never achieve or sustain profitability or may need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; and (xvii) the costs of the proposed transaction. The forward-looking statements contained in this press release are also subject to additional risks, uncertainties and factors, including those described in Breeze Holdings’ most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other documents filed or to be filed with the SEC by Breeze Holdings from time to time. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. The forward-looking statements included in this press release are made only as of the date hereof, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date hereof. Forecasts and estimates regarding YD Biopharma’s industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Annualized, pro forma, projected and estimated numbers are used for illustrative purposes only, are not forecasts and may not reflect actual results.

No Offer or Solicitation

This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities in respect of the proposed transaction and is not a substitute for the Proxy Statement/Prospectus or any other document that Breeze Holdings may file with the SEC or send to Breeze Holdings’ or YD Biopharma’s stockholders in connection with the proposed transaction. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Contacts:

YD Biopharma Limited

Bob Chiu

bobc95@udn-pharm.com

Breeze Holdings Acquisition Corp.

Investor Relations

Cody Slach and Cody Cree

Gateway Group

(949) 574-3860

BREZ@gateway-grp.com

4